3D printing from a clinical perspective
Prof. Dr. Dr. Bilal Al-Nawas, Universität Mainz
Automation in a clinical context
Prof. Dr.-Ing. Jan Stallkamp, Fraunhofer IPA, PAMB Projektgruppe
Future of clinical aspects of MR / CAT compatible devices
Prof. Dr. H. Peter Rodemann, Universität Tübingen
Challenges in production technology: surfaces and interfaces involving living organisms
Dr. Dagmar Martin, Universität Tübingen - Naturwissenschaftliches und Medizinisches Institut (NMI)
Manufacturing of microsystems for healthcare applications
Prof. Dr. Roland Zengerle, Universität Freiburg
Future of hybrid manufacturing for medical devices
Prof. Russel Harris, University of Leeds
Additive manufacturing in medical devices – Status & challenges
Martin Bullemer, EOS GmbH Electro Optical Systems
Cleanroom technology in healthcare manufacturing
Guido Kreck, Fraunhofer IPA
Forschung in 3D-Druck orthopädischer Implantate
Hans Keller, Aesculap AG
Medical device assembly - Mass production trends
Jean-François Bauer, Mikron SA Boudry
Current regulatory challenges in medical device manufacturing
Dr. Faraj Abdelnour, AB Certification
Regulatory changes for medical devices
Prof. Dr. rer.hum.biol. Felix Capanni, Hochschule Ulm
Regulatory changes in manufacturing surgical instruments
Prof. Dr.-Ing. Kurt Greinwald, HFU Tuttlingen
Current regulatory challenges for instrument manufacturers
Dr. Yvonne Glienke, MedicalMountains AG
Herausforderungen für Medizintechnikproduzenten aus Sicht des „Cluster Medizintechnologie Mannheim"
Dr. Elmar Bourdon, Stadt Mannheim - Cluster Medizintechnologie
Despite the relatively small population of Nordic markets, their liberal approach to spending on healthcare and innovative technologies makes the region an attractive option for device manufacturers looking to expand their interests. As some of the best funded markets globally, these rich economies are achieving world-class healthcare outcomes, with a strong focus on patient centricity.
This event offers an introduction to the Nordic market, insight into the regulatory environment and the impact of the forthcoming MDR & IVDR directives. You will also have the opportunity to learn about two test bed projects in the Nordics, working to establish best practice for the testing of products and devices across the region to improve product quality and the patient experience, as well as reducing development costs.
Join this free event to learn more about this innovative, forward thinking market with plentiful opportunities for investment. Network with key stakeholders from across the region and take away key learnings from ongoing projects.
8:30-9:00 – Breakfast & Networking
9:00-9:05 Welcome from the Chair
9:05-9:30 Nordic Market Overview: What are the opportunities?
Bent-Hakon Lauritzen, Project Leader, Oslo MedTech
9:30-10:00 New regulatory frameworks - how forthcoming MDR & IVDR directives will be implemented in the Nordics
Tom Ståhlberg, Director, Finnish Health Technology Association
10:00-10:30 Nordic Testbeds Projects – Establishing best practice for testing and development in Nordic hospitals
Bent-Håkon Lauritzen, Advisor Market Development, Oslo Medtech
Arvid Loeken, Senior Innovation Advisor, Nordic Innovation Centre for Health and Technology, Oulu
Pricing and reimbursement often comes top of the list of industry’s biggest concerns, with many manufacturers now trying to think about reimbursement earlier in the product development process. What are payer’s looking for? How can we improve clinical outcomes whilst simultaneously lowering costs?
Module Chair: Kel Koenen, Head of Content, UBM
The Pricing and Reimbursement Roadmap for Medical Devices in Europe
Carole Jones, Voisin Consulting
The Cost Effectiveness Plan – How to Incorporate Health Economics into your Product Design?
Stuart Hendry, CEO, Heco Anaytics
Funding opportunities in Germany: grants and subsidies to support your business
- What Government schemes are available to support your investment?
- Exploring funding options to help you grow your business
- Which funding program is the best fit for your organisation?
Torsten Eichel, General Manager, Huebner & Partner Innovation
Hear from our shortlisted start-ups on the latest innovations and learn more about opportunities for partnering and collaboration.
10:30-10:35 Welcome from the Chair
10:35 - 10:50 Personal MedSystems GmbH
10:50 -11:05 Acquandas
11:05 - 11:20 Beyond Devices
11:20 – 11:35 Ultramed
11:35 – 11:50 OT Medizintechnik GmbH
11:50-12:00 Q&A with Participants
Once distinct entities, Pharma and Med tech are becoming increasingly aligned in their interests. No longer able to rely purely on the strength of their compounds, Pharma companies are increasingly looking to device manufacturers to explore how to add value to products in their portfolios.
Module Chair: Faraj F. Abdelnour, Director, AB Certification
How Pharma and Medtec are realigning their interests
Unmesh Lal, Program Manager, Frost & Sullivan
Medtech Meets Pharma through Regenerative Medicine
- To what extent is Pharma getting involved in stem cell therapy and its regulatory affairs?
- How are Medtech and Pharma working together in the field of engineering regenerative medicine products?
- How has stem cell research and therapy in medical technology caught the attention of Pharma companies?
Professor Alexander M. Seifalian, Director of Nanotechnology & Regenerative Medicine, The London BioScience Innovation Centre
Combination/borderline products: the rapid evolution from exotic border-crossers to pharma blockbuster products
• As primary containers for liquid drugs evolve into sophisticated delivery systems, the pharma products making use of them become a new breed of regulatory entities
• The US and EU markets follow largely the same concept and regulatory requirements
• US FDA has outlined specific additional requirements for combination products
• Scrutiny of the device part of regulatory submissions increasing significantly
• Pharma development processes are now challenged to comply with concepts from the medical device world: requirements engineering, usability engineering, risk management, design control
• The need for efficient approaches to compliance
Dr. Dirk Kreder, MBA, Founder and CEO, Anteris Medical
Daniel Shoukier, Task Force Member, the ENTOURAGE
You’ve got an interesting concept, but how do you bring it to market?
Medical device clinical trials – Just the necessary evil or a crucial competitive factor?
Axel Fischer, CEO & Founder, Activoris Medizintechnik GmbH
Martin Conrad, Consultant & Head of Market Research, HiTec Consult
Innovation to realisation in practice- Opportunities for SMEs
- Navigating increased regulatory challenges and complex patent landscapes
- What tools and resources exist for SMEs?
- Examining a Case Study from the UK
Keith Heaton, Managing Director, i2r Medical Ltd
Implementing process design early on in the product development process
- Why process design? Often, process design only takes place in the transfer to mass production phase by which time your product is already designed, validated and approved by the notified body and may not adhere to smart mass production methods.
- How to introduce process design during the product design stage to get your product to market quicker
- Tools for implementing effective process design to save time, money and resources.
Shlomi Rom - Director, Business Development - Quasar
The industry is heavily focused on the evolution of device miniaturization. Minimally invasive, micro-surgeries are increasingly becoming an option for patients, enabling less time in hospital, quicker recovery and an overall improved patient experience. Manufacturers must focus on miniaturisation of devices whilst retaining safety, performance and reliability.
Module Chair: Faraj F. Abdelnour, Director, AB Certification
CerMet based encapsulation and feedthrough technology enables new designs and unprecedented potential for miniaturization for sensors and active medical implants
-High end therapy requires highly integrated and miniaturized active medical implants (retina- and cochlea implants, neuro-interfaces, miniaturized medical sensors)
- Encapsulation and feedthrough technology did (over the past decades) not keep up with the developments of electronics and software and is becoming more and more a bottleneck for therapy developments
- A new biocompatible material technology is presented that will enable a significantly increased number of communication ports, 3D-Design and integrated functionality and unprecedented potential for miniaturization.
Jens Trotzschel, Vice President Advanced Technologies, Heraeus Medical Components
Innovative approaches to micro moulding of disposables for diagnostics
- Future lab and diagnostic applications require the dispensing of liquids in the range of µl and nl volumia.
- Current liquid handling systems are very often not precise enough to fulfill these requirements, a look at innovative new handling technologies to meet this need.
- How this new approach results in very precise micro-wells in a reproducible high quality.
Harald Grün, Executive Partner, MDX Devices
Miniaturized Medical Devices using Advanced Substrate Technologies
- Thin film technology provides superb possibilities for miniaturization with pattern resolution in the sub-10µm region
- Circuits manufactured with biocompatible materials (metals and insulators)
- Advanced PCB technologies for higher integration density for medical devices
Alexander Kaiser, Senior Technology Advisor, Cicor
What is the current market outlook for investment and mergers in Med tech? After a bumper year of acquisitions in 2016, what does the M&A market landscape look like for 2017? And with investment becoming harder to come by, what are Venture Capitalists looking for?
Drivers of M&A and Investment in the sector
- An Overview of recent M&A and private equity investment in recent years
- What are the key drivers behind this activity?
- Industry structure, supply chain and economic fundamentals.
- Deal activity, sector performance, and valuation trends.
- Outlook for 2017 and beyond
Nicholas Mockett, Partner, Moorgate Capital
Panel discussion: What are VCs looking for?
- Overview of 2017 market trends for financing and investment
- Will Venture Capital continues its trend towards fewer deals, how will this affect the market?
- What are VCs looking for to invest in start-ups and innovative enterprises?
Dr Aristotelis Nastos, Partner, Creathor Venture (confirmed)
Dr. Joachim Rautter, Managing Director, Peppermint VenturePartners GmbH (confirmed)
Dr Karsten Fischer, Partner, Biomed Invest (confirmed)